Ironwood Pharmaceuticals (IRWD) Q4 2023 earnings summary

Executive summary

• 2023 priorities advanced LINZESS growth, GI pipeline development and sustained profitability; LINZESS received FDA approval for pediatric functional constipation ages 6–17.

• VectivBio acquisition added apraglutide; positive final STARS Nutrition Phase 2 data and favorable early T-cell response evidence for CNP-104 were reported.

• 2024 priorities include maximizing LINZESS, advancing GI pipeline programs, and delivering sustained profits and cash flows.

Financial highlights

• FY 2023 revenue was $442.7M versus $410.6M in 2022; Q4 revenue was $117.6M versus $107.2M.

• FY 2023 GAAP net loss was $1,002M, or $6.45 per share; adjusted EBITDA loss was $884.8M.

• Q4 2023 GAAP net loss was $1.7M and adjusted EBITDA was $39.9M.

• Cash from operations was $183.4M for FY 2023 versus $273.8M in 2022; Q4 cash from operations was $35.8M.

• FY 2023 results included a one-time $1.095B acquired in-process R&D charge related to the VectivBio acquisition.

Outlook and guidance

• FY 2024 guidance: U.S. LINZESS net sales growth in the low single digits, total revenue of $435M–$455M, and adjusted EBITDA above $150M.

• Adjusted EBITDA guidance excludes potential CNP-104 option exercise costs and assumes no material 2024 business development expenses.

• Apraglutide STARGAZE topline results were expected in March 2024; CNP-104 data in Q1 2024 and IW-3300 topline results in Q3 2024.